Ocular Therapeutix (OCUL) Invested Capital (2021 - 2023)

Ocular Therapeutix's Invested Capital history runs 3 years deep, the most recent figure standing at $20.0 million for Q4 2023.

• On a quarterly basis, Invested Capital fell 19.9% year-over-year to $20.0 million in Q4 2023; TTM through Sep 2024 was $20.0 million, a 59.95% decrease from a year earlier, with the FY2023 full-year figure at $20.0 million, down 19.9% from the prior year.
• Invested Capital retreated to $20.0 million in Q4 2023 per OCUL's latest filing, from $25.0 million in the prior quarter.
• Across five years, Invested Capital topped out at $25.0 million in Q2 2021 and bottomed at $20.0 million in Q4 2023.
• The 3-year median for Invested Capital is $25.0 million (2021), against an average of $24.2 million.
• Across the five-year window, Invested Capital changed 0.0% in 2022 and decreased 19.9% in 2023, its largest moves.
• Year by year, Invested Capital stood at $25.0 million in 2021, then changed by 0.0% to $25.0 million in 2022, then dropped by 19.9% to $20.0 million in 2023.
• Per Business Quant, the three latest OCUL Invested Capital figures stand at $20.0 million (Q4 2023), $25.0 million (Q1 2023), and $25.0 million (Q4 2022).